These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 17896900

  • 21. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun 06; 47(1210):45-6. PubMed ID: 15933616
    [Abstract] [Full Text] [Related]

  • 22. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N.
    South Med J; 2006 Nov 06; 99(11):1271-9. PubMed ID: 17195423
    [Abstract] [Full Text] [Related]

  • 23. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA.
    Int J Obes (Lond); 2006 Sep 06; 30(9):1332-40. PubMed ID: 16534527
    [Abstract] [Full Text] [Related]

  • 24. Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
    Al-Jebawi AF.
    Diabetes Res Clin Pract; 2010 Dec 06; 90(3):e88-90. PubMed ID: 21030101
    [Abstract] [Full Text] [Related]

  • 25. Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
    Oriot P, Hermans MP, Selvais P, Buysschaert M, de la Tribonnière X.
    Ann Endocrinol (Paris); 2011 Jun 06; 72(3):244-6. PubMed ID: 21652029
    [Abstract] [Full Text] [Related]

  • 26. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
    Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R.
    J Med Econ; 2011 Jun 06; 14(6):705-8. PubMed ID: 21892855
    [Abstract] [Full Text] [Related]

  • 27. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC, Grasso P.
    Regul Pept; 2012 Nov 10; 179(1-3):33-8. PubMed ID: 22960403
    [Abstract] [Full Text] [Related]

  • 28. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.
    Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977
    [Abstract] [Full Text] [Related]

  • 29. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B.
    Soins; 2008 Jun 07; (726):34-7. PubMed ID: 18697336
    [No Abstract] [Full Text] [Related]

  • 30. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG, Klein MS, Jernigan MJ, Wise SL, Frugé K.
    Pharmacotherapy; 2013 Jun 07; 33(6):627-38. PubMed ID: 23553357
    [Abstract] [Full Text] [Related]

  • 31. Exenatide. Amylin/Eli Lilly.
    Giannoukakis N.
    Curr Opin Investig Drugs; 2003 Apr 07; 4(4):459-65. PubMed ID: 12808888
    [Abstract] [Full Text] [Related]

  • 32. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
    Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J.
    Can J Diabetes; 2014 Aug 07; 38(4):269-72. PubMed ID: 24797495
    [Abstract] [Full Text] [Related]

  • 33. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M.
    Regul Pept; 2008 Nov 29; 151(1-3):123-9. PubMed ID: 18675854
    [Abstract] [Full Text] [Related]

  • 34. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N, McCombs JS, Schwartz E.
    Clin Ther; 2012 May 29; 34(5):1145-58. PubMed ID: 22464691
    [Abstract] [Full Text] [Related]

  • 35. Diabetes medications and body weight.
    Mitri J, Hamdy O.
    Expert Opin Drug Saf; 2009 Sep 29; 8(5):573-84. PubMed ID: 19538102
    [Abstract] [Full Text] [Related]

  • 36. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M, Troskot R.
    Minerva Endocrinol; 2015 Mar 29; 40(1):71-83. PubMed ID: 25366984
    [Abstract] [Full Text] [Related]

  • 37. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul 29; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 38. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
    Schnabel CA, Wintle M, Kolterman O.
    Vasc Health Risk Manag; 2006 Jul 29; 2(1):69-77. PubMed ID: 17319471
    [Abstract] [Full Text] [Related]

  • 39. Use of exenatide for weight loss in patients with diabetes.
    Virji A.
    Am Fam Physician; 2007 May 01; 75(9):1304. PubMed ID: 17511061
    [No Abstract] [Full Text] [Related]

  • 40. Exenatide and acute pancreatitis.
    Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A.
    J Assoc Physicians India; 2008 Dec 01; 56():987-8. PubMed ID: 19322980
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.